Division of Samsung Electronics Co. Ltd.
Latest From Samsung BioLogics
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.
Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
In the third and final part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko talks about the importance of real-world data in bolstering biosimilars, as well as outlining the firm’s future pipeline.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Samsung-Quintiles joint venture
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Samsung Electronics Co. Ltd.
- Senior Management
Tae Han Kim, PhD, CEO
Dongjoong Kim, CFO
- Contact Info
Phone: 2 2255 8500
300 Songdo Bio Way
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.